Nycomed to market Roche osteoporosis product in Asia-Pacific markets
This article was originally published in Scrip
Executive Summary
Nycomed is to market Roche's osteoporosis treatment Bonviva (ibandronate) in a number of Asia-Pacific markets following the transfer of marketing authorisation approvals.